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Abstract
B lymphocyte egress from secondary lymphoid organs requires sphingosine-1-phosphate (S1P) and S1P receptor-1 (S1P1).
However, whether S1P contributes to immature-B cell egress from the bone marrow (BM) has not been fully assessed. Here
we report that in S1P- and S1P1-conditionally deficient mice, the number of immature-B cells in the BM parenchyma
increased, while it decreased in the blood. Moreover, a slower rate of bromodeoxyuridine incorporation suggested
immature-B cells spent longer in the BM of mice in which S1P1-S1P signaling was genetically or pharmacologically impaired.
Transgenic expression of S1P1 in developing B cells was sufficient to mobilize pro- and pre-B cells from the BM. We
conclude that the S1P1-S1P pathway contributes to egress of immature-B cells from BM, and that this mechanism is partially
redundant with other undefined pathways.
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Introduction
In late stages of B cell development in the bone marrow (BM),
newly generated immature-B cells become partitioned between the
BM parenchyma and sinusoids [1,2,3]. Immature-B cells are
retained in the sinusoidal compartment for a short period before
entering the blood circulation [3]. Sinusoidal entry is thought to be
a key step in egress commitment yet the requirements for this
migration event remain poorly defined.
Egress of lymphocytes from the thymus and from peripheral
lymphoid organs requires a concentration gradient of Sphingosine
1-Phosphate (S1P)[4,5].S1PisrecognizedbyS1Preceptor-1(S1P1)
expressed on lymphocytes, and deficiency in S1P1results in a severe
egress block from the thymus and lymph nodes [6]. The small
molecule FTY720 functionally antagonizes the activity of S1P1,
blocks lymphocyte egress from secondary lymphoid organs, and
causes peripheral lymphopenia [6,7,8]. Despite this major role in
egress, deficiencies in S1P or S1P1 did not reveal a dominant role
for this ligand-receptor system during B cell egress from the BM
[4,6]. In short-term adoptive transfer experiments S1P1-deficient
mature B cells accumulated in the BM, but a role for S1P1 in egress
was not established [9]. Recently, NK cells were shown to require
intrinsic S1P5 expression for BM egress and conditional deficiency
in both S1P-generating enzymes, Sphingosine kinase (Sphk)-1 and -
2, reduced NK cell egress from the BM [10,11]. Monocyte egress
from the BM has been suggested to be promoted by S1P receptor
agonist treatment though a direct effect of S1P receptor or S1P
deficiency on monocyte egress has not yet been demonstrated [12].
Here we show that in mice conditionally deficient in S1P1 in B-
lineage cells, egress of immature-B lymphocytes from the BM was
slightly but significantly reduced. In S1P-deficient mice immature-
B cell egress was also diminished. Reciprocally, premature
expression of S1P1 from a transgene was sufficient to mobilize
pro- and pre-B cells into the periphery. These findings indicate
that the S1P-pathway contributes to the mechanism of B cell
egress from the BM.
Materials and Methods
Mice, Chimeras, In Vivo FTY720 Treatments, and BrdU
Labeling
Adult C57Bl/6 (Ly5.2
+) mice aged 6–8 weeks were from the
National Cancer Institute, and adult Boy/J (Ly5.1
+; stock
no. 002014) mice were from The Jackson Laboratories. Edg1
fl/fl
and Edg1
+/2 mice (obtained from Dr. Richard Proia, National
Institute of Diabetes and Digestive and Kidney Diseases, Bethesda,
MD) were crossed with Mb1
Cre/+ [13] (Dr. M. Reth, Max-Planck
Institute of Immunobiology, Freiburg, Germany) to generate
Edg1
fl/2Mb1
Cre/+ and Edg1
+/+Mb1
Cre/+. Sphk1
fl/2 Sphk2
2/2 mice
[4] were provided by Dr. Shaun Coughlin (University of
California San Francisco, CA) and carried an Mx-Cre transgene
[14]. BM chimeras were prepared as described [3], and analyzed
at least 6 weeks after reconstitution. FTY720 was from a custom
synthesis by Stanford Resesarch Institute (Palo Alto, CA). Adult
C57Bl/6 mice were treated with FTY720 at 1 mg/Kg (or saline)
intravenously (i.v.) for 3 h or 3 days. BrdU labeling experiments
were as described [3]. Animals were housed in a specific pathogen-
free facility, and all experiments were performed in accordance
with protocols approved by the University of California San
Francisco Institutional Animal Care and Use Committee.
Generation of S1P1 Transgenic Mice
A DNA fragment encoding mouse Edg1 mRNA was PCR
amplified from pMSCV-Flag-Edg1, with the following primers:
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(containing a 59 BamHI restriction site) and reverse 59- CAT GCT
CGA GTT ATT AGG AAG AAG AA -39 (containing a XhoI
restriction site). The PCR product was digested with BamHI and
XhoI restriction enzymes (Roche) and cloned into the plasmid
p1026x containing the immunoglobulin Em heavy chain enhancer
and the Lck proximal promoter [15]. The NotI linearized plasmid
was microinjected into fertilized (C57BL/6 x DBA/2J) oocytes
according to standard procedures. Transgenic mice (line D) were
screened by PCR using the primers described below. All the
transgenic mice analyzed were heterozygous for the transgene, and
segregated at the expected Mendelian rate. All mice were healthy
at all ages tested.
In Vivo Labeling of Bone Marrow Sinusoidal B Cells and In
Vitro Migration Assays
Sinusoidal B cells were labeled as described [3]. In FTY720,
and BrdU treatments, in vivo labeling was performed in the last 2
minutes of the indicated treatments. Developing B cell subsets
were gated according to Hardy’s nomenclature [16], with
modifications, as described [3]. Briefly, pro-B and pre-B cells
were gated as forward scatter large and small B220
+ (PE-Cy5.5
conjugated clone RA3-6B2, Biolegend), CD93
+ (APC conjugated
clone AA4.1, eBioscience), IgM
2 (FITC conjugated Goat anti
mouse IgM, Jackson Immunoresearch) and IgD
2 (biotin-conju-
gated Rat anti mouse IgD, clone 11–26, Southern Biotech.),
revealed with streptavidin QD605, (Molecular Probes) lympho-
cytes, respectively; immature-B cells were divided into two
populations: B220
+CD93
+IgM
+IgD
2 and B220
+CD93
+IgM
+Ig-
D
lo; mature recirculating B cells were isolated as B220
+CD93
2Ig-
M
+IgD
hi cells. Chemotaxis assays to S1P (Sigma) or CXCL12
(R&D) were performed as described [17].
Cell Sorting and mRNA Analyses
BM cells were stained at 40610
6 cells/mL, and B cell subsets
were identified as described. Cells were sorted with a BD FACS
ARIA instrument, and the purity of sorted populations was .97%.
Quantitative PCR (ABI 7700 PE Applied Biosystems) was
performed with the following primers/probes (Integrated DNA
Technologies): Edg1 forward 59- ccttcatccggatcgtatct -39, and
reverse 59- tgctgcggctaaattccatg -39. Edg1 amplification was as
follows: 35 cycles 94uC for 20 s; 55uC for 20 s; and 72uC for 30 s;
other primers used were as described [3].
Results
Reduced BM Egress of S1P1-Deficient Immature-B Cells
In adult wild type mice, two subsets of BM immature
CD93
+IgM
+ B cells can be distinguished based on surface IgD
expression (Figure 1A). To distinguish by flow cytometry B cell
subsets that were in the BM parenchyma, or in sinusoids, we
injected 1 mg of phycoerythrin (PE)-conjugated anti-CD19 intra-
venously and allowed the antibody to equilibrate for 2 minutes, an
exposure period that achieves selective labeling of sinusoidal B
cells [3]. Whereas the number of immature CD93
+IgM
+IgD
2 and
CD93
+IgM
+IgD
lo cells was similar in the BM parenchyma
(Figure 1B and D), the IgD
lo subset was more abundant in BM
sinusoids (Fig. 1B and D), and approximately 10-fold enriched in
the peripheral blood (Figure 1C and D). This observation suggests
that progression into the IgD
lo stage coincides with a higher
propensity of these cells to egress from the BM parenchyma into
sinusoids, and then into circulation.
Analysis of S1P receptor-encoding transcript abundance in
sorted BM B cell populations revealed S1P1 to be the most
abundant receptor, already expressed in pre-B cells (Figure 2A).
Figure 1. Progression into the Immature IgD
lo B cell stage coincides with increased egress efficiency. (A) Expression of IgM and IgD in
B220
+ BM B-lineage cells. Numbers indicate percent of total B220
+ cells. (B) Distribution of the indicated B-lineage populations in BM parenchyma and
sinusoids. Numbers indicate percent of cells from each subset residing in sinusoids. (C) Expression of IgM and IgD in B220
+ B-lineage cells in peripheral
blood. Numbers indicate percent of total B220
+ cells. (D) Enumeration of developing B cell subsets in BM parenchyma and sinusoids, and peripheral
blood. In all panels, data shown are representative of more than 10 independent experiments. ** P,0.005 (unpaired, two-tailed Student’s t-test).
doi:10.1371/journal.pone.0009277.g001
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S1P5 was undetectable (Figure 2A). To assess if S1P1 plays a role
in immature-B cell egress from the BM we analyzed the
distribution of developing B cells in BM parenchyma and
sinusoids, peripheral blood and spleens of mice in which S1P1
was conditionally ablated in B-lineage cells (hereafter designated as
S1P1-deficient). In S1P1-deficient mice, the number of immature
IgD
lo B cells was slightly, but significantly, increased in the BM
parenchyma, and reduced by 2.1-fold in peripheral blood
(Figure 2B). This difference contrasted with similar numbers of
BM parenchymal Pro-B, Pre-B and immature IgD
2 B cells, thus
suggesting that BM egress of immature IgD
lo cells might be
specifically reduced in S1P1-deficient mice. The number of
immature IgD
lo cells in sinusoids seemed, however, unaffected
(Figure 2B). Mature B cells were significantly reduced in BM,
blood and spleen (Figure 2B), as previously reported [6]. Given
that egress of hematopoietic cells from the BM is thought to occur
via BM sinusoids, it was surprising to find that while S1P1-
deficient immature-IgD
lo cells accumulated in parenchyma, their
numbers seemed unaffected in sinusoids. However, the absolute
cell numbers present in BM sinusoids are small and variable
between mice (Figure 2B). To facilitate detection of even small
changes in cell representation in sinusoids, we turned to a mixed
BM chimera approach that would allow comparison of wildtype
and S1P1-deficient cell frequencies in sinusoids of the same
animals. We analyzed the distribution of B cell subsets in BM
parenchyma and sinusoids of mice reconstituted with mixtures of
Edg1
fl/2 Mb1
Cre/+ or Edg1
+/+ Mb1
Cre/+ (Ly5.2) and wild type
(Ly5.1) BM. We found an accumulation of S1P1-deficient
immature IgD
lo B cells in the BM parenchyma (Figure 2C),
consistent with the above findings (Figure 2B). Moreover, by this
approach we found that the fraction of S1P1-deficient immature
IgD
2 and IgD
lo B cells was reduced in sinusoids (Figure 2C),
suggesting that egress from BM parenchyma into sinusoids was
reduced.
As an approach to test whether S1P signaling acts continually to
promote immature-B cell egress from BM we treated C57BL/6
mice with FTY720 (1 mg/Kg). After a 3 h treatment there was a
significant accumulation of immature IgD
lo cells in BM, and a 3-
fold reduction in peripheral blood (Figure 2D), consistent with a
reduced rate of BM egress and recirculation.
Reduced Egress of Immature-B cells from BM of S1P-
Deficient Mice
S1P1 is sensitive to down-modulation by ligand, and surface
levels on CD4 T cells are high when cells are in low S1P
environments and low when cells are in high S1P environments
[4,17]. Flow cytometric analysis of BM parenchymal and
sinusoidal naı ¨ve CD4
+ T cells showed detectable surface S1P1
on parenchymal cells compared to a lack of surface receptor on
sinusoidal cells (Figure 3A) as recently reported [10], indicating
that S1P concentrations are lower in the parenchyma than in
sinusoids. Mice conditionally deficient in Sphk1 and Sphk2 (Sphk-
deficient) showed normal numbers of developing B cells in BM,
but their distribution was not assessed [4]. Thus, we revisited B cell
development in Sphk-deficient mice, analyzing positioning of B cell
subsets in BM by flow cytometry. We found a small but significant
increase in the number of parenchymal immature IgD
lo cells, and
a reduction in their numbers within sinusoids (Figure 3). The
number of immature IgD
lo cells was approximately 2.6-fold lower
in peripheral blood of S1P-deficient mice than in littermate
controls. The accumulation in BM parenchyma and reduction in
peripheral blood suggests that S1P also contributes to immature-B
cell egress from BM (Figure 3).
If BM egress of developing B cells is defective then their time of
residence in the BM might be increased. To explore this possibility
we analyzed the rate of BrdU incorporation in BM B cell subsets of
Edg1
fl/2 Mb1
Cre/+ or Edg1
+/+ Mb1
Cre/+ (Ly5.1) and wild type
(Ly5.2) mixed BM chimeras, and in Sphk-deficient and control
littermates, by feeding them BrdU (1 mg/mL) in the drinking
Figure 2. Impaired BM egress of S1P1-deficient immature-B cells. (A) Quantitative RT-PCR analysis of transcript abundance for the genes
encoding S1P1 (Edg1), S1P2 (Edg5), S1P3 (Edg3), S1P4 (Edg6) and S1P5 (Edg8) in purified developing BM B cell subsets presented relative to Hprt1.
Data shown are representative of 3 experiments. (B) Number of B cells in indicated subsets in the BM parenchyma and sinusoids, peripheral blood
and spleens of Edg1
Fl/2 Mb1
Cre/+ (gray bars) and Edg1
+/+ Mb1
Cre/+ (white bars) mice. Data are pooled from 4 independent experiments. (C) Analysis of
B cell development in chimeras reconstituted with mixtures of Edg1
Fl/2 Mb1
Cre/+ (gray bars, Ly5.2
+)o rEdg1
+/+ Mb1
Cre/+ (white bars, Ly5.2
+) and wild-
type (Ly5.1
+) BM. Shown is the ratio of Ly5.2
+ cells in the indicated developmental subsets with that of Pro-B cells in the same animal. Data are pooled
from 3 independent experiments. (D) Number of developing B cells in total BM, blood and spleens of mice treated with FTY720 (1 mg/Kg, gray bars)
or with saline (white bars) for 3 h. Data shown are representative of more than 3 independent experiments. * P,0.05; ** P,0.005 (unpaired, two-
tailed Student’s t-test).
doi:10.1371/journal.pone.0009277.g002
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+ S1P1-deficient
immature IgD
2 and IgD
lo B cells was significantly reduced, as
compared to the fraction of BrdU
+ S1P1-sufficient immature-B
cells (Figure 4A). Pre-B cells became similarly BrdU labeled in the
two groups indicating that S1P1-signaling is not required for Pro-B
and Pre-B cell expansion or survival. Thus, the reduced frequency
of BrdU
+ immature-B cells likely reflects an increase in the
proportion of these cells that resided in BM for a period longer
than the 48 h of continuous BrdU treatment. Sphk-deficient mice
also showed lower 48 h BrdU labeling of IgD
lo immature-B cells
compared to littermate controls (Figure 4B). Similarly, in wild-type
C57BL/6 mice treated with FTY720 for 3 days we found a
reduced fraction of 24 h and 48 h BrdU-labeled immature-B cells
(but not Pre-B cells) in BM parenchyma, sinusoids, blood and
spleen (Table 1 and Figure 4C). The similar rate of BrdU
incorporation at 24 h and 48 h in Pro-B and Pre-B cells suggests
that the S1P/S1P-receptor pathway is not required during early
stages of B cell development. However, these findings suggest a
slower rate of immature-BM B cell replacement by newly
generated cells, consistent with a role for the S1P-pathway in
BM egress.
Premature Egress of Pro- and Pre-B Cells in S1P1-
Transgenic Mice
Finally, we asked if enforced expression of S1P1 in B
lymphocytes was sufficient to promote premature egress of
developing B cells. We generated transgenic mice expressing
S1P1 under the control of the immunoglobulin heavy chain Em
enhancer and Lck proximal promoter, and analyzed S1P1
expression during B cell development. S1P1 transcripts were
significantly increased already at the Pro-B cell stage and remained
higher in transgenic B cell subsets than in cells from littermate
controls (Figure 5A). Moreover, in vitro chemotaxis assays showed
increased migration of S1P1-transgenic Pro-B, Pre-B, and
immature-B cells to S1P, indicating that S1P1 is functional in
these cells (Figure 5B). Migration of B cell subsets from S1P1-
transgenic and littermate controls to SDF-1 was similar (Figure 5B).
Analysis of developing B cell numbers showed a 10-fold increase in
Pro- and Pre-B cells in sinusoids, peripheral blood and spleens of
S1P1-transgenic mice (Figure 5C). Immature-B cell distribution
was altered as well, with reduced numbers in the BM parenchyma
and increased numbers in sinusoids, blood and spleen (Figure 5C).
Even though Pro- and Pre-B cells were substantially increased in
sinusoids, blood and spleen, the total number of cells detected in
Figure 3. S1P1 surface expression in BM parenchymal and
sinusoidal cells and impaired egress of immature-B cells from
the BM of S1P-deficient mice. (A) S1P1 surface expression in BM
parenchymal and sinusoidal naı ¨ve CD4
+ T cells. Mice were treated with
Ly5.2-PE antibodies intravenously for 2 minutes. T cells were gated as
TCRb
+ CD4
+ CD8
2 L-sel
+, and further gated as parenchymal (Ly5.2
2,
black) and sinusoidal (Ly5.2
+, gray). Top panel shows cells stained with a
control rabbit antiserum, and bottom panel shows cell staining with an
anti-S1P1 rabbit antiserum. Data are representative of two experiments
(n=6). (B) Number of developing B cell subsets in the BM parenchyma,
sinusoids, blood and spleen of Sphk-1 and -2-deficient and littermate
control mice. Data shown were pooled from 4 independent experi-
ments. * P,0.05; ** P,0.005 (unpaired, two-tailed Student’s t-test).
doi:10.1371/journal.pone.0009277.g003
Figure 4. Prolonged residence of immature-B cells in BM of
S1P1 or S1P deficient mice. (A) Analysis of BrdU incorporation for
48 h in developing B cell subsets in chimeras reconstituted with
mixtures of Edg1
Fl/2 Mb1
Cre/+ (gray bars, Ly5.2
+)o rEdg1
+/+ Mb1
Cre/+
(white bars, Ly5.2
+) with wild-type (Ly5.1
+) BM. Shown is the ratio of
percent BrdU
+ Ly5.2
+ and BrdU
+ Ly5.1
+ cells in the indicated
developmental subsets. Data are pooled from 3 independent experi-
ments. (B) BrdU incorporation for 48 h in developing B cell subsets from
Sphk-1 and -2-deficient (gray bars) and littermate controls (white bars).
Data shown were pooled from 2 independent experiments. (C) BrdU
incorporation for 48 h in developing B cell subsets from mice treated
with saline (white bars) or FTY720 (1 mg/Kg; gray bars) for 3 days. Data
shown are representative of 3 independent experiments. In all panels,
bars indicate the mean, circles indicate individual mice. * P,0.05;
** P,0.005 (unpaired, two-tailed Student’s t-test).
doi:10.1371/journal.pone.0009277.g004
Table 1. Frequency of BrdU
+ cells in the indicated BM B cell
developmental subsets from mice treated with saline or
FTY720 (1 mg/Kg) for 3 days, and continuously exposed to
BrdU in the last 24 h.
*Cell
Subset Pro-B Pre-B IgM
+IgD
2 IgM
+IgD
lo Mature-B
Saline 88.566.5 63.765.2 31.861.6 16.361.8 0.260.1
FTY720 81.069.3 62.263.8 21.467.5 12.963.3 0.260.1
Student’s t 0.29 0.67 0.02 0.07 0.70
*Immature B cell subsets (IgM
+IgD
2 and IgM
+IgD
lo) were gated as CD93
+.
Values indicate Average 6 SD of pooled data from 2 independent experiments
(n=4 in each group).
doi:10.1371/journal.pone.0009277.t001
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4–10
5 and thus insufficient to
cause a measurable decrease from the parenchyma (where the
numbers are in the order of 10
6).
Discussion
Several studies have demonstrated that the S1P-S1P1 pathway
operates to control lymphocyte egress from primary and secondary
lymphoid organs [18]. However, these studies did not reveal a role
for this pathway in immature-B cell egress from the BM. Egress of
BM cells is thought to occur via the vast network of sinusoids that
travels through the parenchyma [19]. By using a pulse-labeling
procedure that specifically labels cells residing in the BM
vasculature [3], we assessed if the S1P-S1P1 pathway contributes
to the immature-B cell distribution between BM parenchyma and
sinusoids. We showed that in mice conditionally deficient in S1P1
in B lineage cells, and in mice in which S1P1 activity was
pharmacologically ablated, immature-B cells accumulated in the
BM parenchyma and were concomitantly reduced in sinusoids
and peripheral blood, suggesting reduced egress efficiency. S1P-
deficient mice also exhibited reduced egress of immature-B cells
from the BM. Reciprocally, transgenic expression of S1P1 early in
B cell development resulted in the mobilization of Pro-B and Pre-B
cells from the BM parenchyma into sinusoids, peripheral blood
and spleen.
Our finding of a reduction in 48 hr BrdU-labeled S1P1- and
S1P-deficient immature-BM B cells compared to wildtype controls
indicated that it takes longer to fully replace S1P1- and S1P-
deficient immature cells with cells newly generated from pre-B
cells. Since the animals showed similar extents of pre-B cell
labeling at 24 h and 48 h, we feel that the simplest interpretation
of these data is that the immature-B cells reside in the BM for a
slightly longer average time due to less efficient egress. We cannot
exclude the possibility that S1P1 and S1P-deficiency somehow
influence other properties of the immature-B cells, such as
reducing the fraction that undergo cell death. However, S1P1
signaling has been found to promote improved cell viability in
some systems [20,21,22], making this explanation seem unlikely.
It was notable that S1P-deficient mice showed a greater
reduction in the sinusoidal immature-B cell population than
observed in S1P1-deficient mice. This result could be explained by
a contribution of additional S1P receptors in egress of immature-B
cells from BM. S1P3 is differentially expressed in developing B cell
subsets, being most abundant in immature IgD
2 and IgD
lo cells,
and in vitro chemotactic responsiveness of immature-B cells to S1P
is predominantly S1P3-mediated, indicating the receptor is
functional in these cells [23,24] (and data not shown). Indeed, as
for marginal zone B cells [25], the activity of S1P3 in the in vitro
S1P chemotaxis assay obscures the activity of S1P1. However,
analysis of B cell development in S1P3-deficient mixed BM
chimeras (n=10) revealed no significant differences in immature-B
cell BM egress (data not shown). A recent study also found a lack
of S1P3 contribution to immature B cell egress from the BM [24].
The basis for the discord between S1P receptor activity in vitro
versus in vivo is unclear but might reflect the high sensitivity of
S1P1 to desensitization [17,26,27] and the lack of appropriate
partioning of S1P distribution in the in vitro assay. S1P4 transcripts
were also detected in immature-B cells and it is possible that this
poorly characterized receptor contributes to the egress mecha-
nism. Alternatively, S1P may have a B cell extrinsic as well as
S1P1-dependent B cell intrinsic effect. For example, endothelial
cells can respond to S1P [28] and S1P-deficiency might lead to
alterations in sinusoidal endothelium that impair retention of
immature and mature B cells. 2-arachydonoyl glycerol (2-AG) can
be produced by endothelial cells [29,30,31], is abundant in the BM
microenvironment [3], and its receptor, cannabinoid receptor 2
(CB2), is required for B cell retention in sinusoids [3]. It will be
important in future studies to determine the 2-AG concentration
in BM of Sphk-deficient mice.
Although S1P1 is already present in pre-B cells, they undergo
minimal egress compared to immature B cells. Concordantly, in
S1P1-transgenic mice S1P1 transcripts are equivalently high in
Pre-B and Immature B cells, yet the immature B cell population
has higher egress efficiency as measured by numerical reduction in
BM parenchyma and increase in sinusoids, peripheral blood and
spleen. Thus, we propose that during B cell development
additional changes occur that confer an increased ability to egress
the BM. These changes may be related to alterations in BM
parenchyma retention, expression of additional egress receptor(s),
or both.
In summary, we suggest that immature-B cell movement from
parenchyma into sinusoid is promoted by S1P1-signaling within
the B cell in response to the higher S1P concentration within the
Figure 5. Premature egress of B cell precursors from the BM of
S1P1-transgenic mice. (A) Quantitative RT-PCR analysis of the
expression of S1P1 encoding mRNA in purified developing BM B cell
subsets from S1P1-transgenic (gray bars) and littermate control (white
bars) mice, presented relative to Hprt1 mRNA (hypoxanthine guanine
phosphoribosyl transferase). Data shown was pooled from 3 indepen-
dent experiments. (B) Migration assays of developing B cells from S1P1-
transgenic (gray bars) and littermate control (white bars) mice to S1P
(100 nM) or SDF-1 (0.3 mg/mL). Data are representative of 4 experi-
ments. (C) Enumeration of developing B cell subsets from S1P1-
transgenic (gray bars) and littermate control (white bars) mice in the BM
parenchyma, sinusoids, peripheral blood and spleen. In all panels, bars
indicate the mean, circles indicate individual mice. * P,0.05; ** P,0.005
(unpaired, two-tailed Student’s t-test).
doi:10.1371/journal.pone.0009277.g005
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cell egress from the BM likely reflects redundancy with additional
mechanisms such as down-regulation of CXCR4-mediated
retention [32,33] and expression of further receptors sensing
sinusoid associated or circulatory chemoattractants.
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